Somewhat Positive Press Coverage Somewhat Unlikely to Impact Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Price

News headlines about Supernus Pharmaceuticals (NASDAQ:SUPN) have trended somewhat positive this week, Accern reports. The research group identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Supernus Pharmaceuticals earned a coverage optimism score of 0.22 on Accern’s scale. Accern also assigned news articles about the specialty pharmaceutical company an impact score of 46.2490379937036 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Shares of SUPN stock traded up $1.05 on Tuesday, reaching $45.20. The stock had a trading volume of 830,489 shares, compared to its average volume of 707,298. The company has a market cap of $2,360.40, a P/E ratio of 35.87 and a beta of 1.11. Supernus Pharmaceuticals has a 1 year low of $29.55 and a 1 year high of $50.04.

How to Become a New Pot Stock Millionaire

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.44 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.26 by $0.18. The firm had revenue of $88.44 million for the quarter, compared to the consensus estimate of $87.84 million. Supernus Pharmaceuticals had a return on equity of 28.07% and a net margin of 18.95%. sell-side analysts expect that Supernus Pharmaceuticals will post 1.85 earnings per share for the current year.

Several research analysts have recently issued reports on SUPN shares. Janney Montgomery Scott raised Supernus Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $47.00 target price for the company in a research report on Monday, December 4th. B. Riley increased their target price on Supernus Pharmaceuticals from $50.00 to $54.00 and gave the stock a “buy” rating in a research report on Thursday, December 28th. Zacks Investment Research lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, January 12th. BidaskClub lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, February 1st. Finally, Berenberg Bank assumed coverage on Supernus Pharmaceuticals in a research report on Thursday, February 1st. They set a “buy” rating and a $66.00 price objective for the company. Two research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $51.36.

In related news, VP Padmanabh P. Bhatt sold 20,000 shares of Supernus Pharmaceuticals stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $48.04, for a total transaction of $960,800.00. Following the transaction, the vice president now directly owns 32,500 shares in the company, valued at $1,561,300. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Victor Vaughn sold 15,000 shares of Supernus Pharmaceuticals stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $42.04, for a total value of $630,600.00. Following the transaction, the vice president now owns 24,344 shares in the company, valued at $1,023,421.76. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 110,750 shares of company stock worth $4,927,923. Company insiders own 6.70% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Price” was reported by BBNS and is owned by of BBNS. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://baseballnewssource.com/2018/04/03/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-supernus-pharmaceuticals-supn-share-price/2015407.html.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Insider Buying and Selling by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Xander Bogaerts Goes on Red Sox DL
Xander Bogaerts Goes on Red Sox DL


Leave a Reply

 
© 2006-2018 BBNS.